Temporomandibular joint pressure pain threshold is systemically modulated in rheumatoid arthritis

Journal of Orofacial Pain

Volumn 22, Issue 3, 2008, Pages 231-238

  Alstergren, Per ^a   Fredriksson, Lars ^a   Kopp, Sigvard ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

Pain; Pain threshold; Serotonin; Temporomandibular joint; Tumor necrosis factor

Indexed keywords

AUTACOID; C REACTIVE PROTEIN; INTERLEUKIN 1 RECEPTOR TYPE II; RHEUMATOID FACTOR; SEROTONIN; TUMOR NECROSIS FACTOR;

ARTICLE; BLOOD; CHEMISTRY; ERYTHROCYTE SEDIMENTATION RATE; FACE PAIN; FEMALE; HUMAN; JOINT CHARACTERISTICS AND FUNCTIONS; MALE; MIDDLE AGED; PAIN ASSESSMENT; PAIN THRESHOLD; PALPATION; PARACENTESIS; PATHOPHYSIOLOGY; PHYSIOLOGY; PRESSURE; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDER; THROMBOCYTE COUNT;

ARTHRITIS, RHEUMATOID; BLOOD SEDIMENTATION; C-REACTIVE PROTEIN; FACIAL PAIN; FEMALE; HUMANS; INFLAMMATION MEDIATORS; MALE; MIDDLE AGED; PAIN MEASUREMENT; PAIN THRESHOLD; PALPATION; PARACENTESIS; PLATELET COUNT; PRESSURE; RANGE OF MOTION, ARTICULAR; RECEPTORS, INTERLEUKIN-1 TYPE II; RHEUMATOID FACTOR; SEROTONIN; SYNOVIAL FLUID; TEMPOROMANDIBULAR JOINT DISORDERS; TUMOR NECROSIS FACTORS;

EID: 49749139791     PISSN: 10646655     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Fredriksson L, Alstergren P, Kopp S. Pressure pain thresholds in the craniofacial region of female patients with rheumatoid arthritis. J Orofac Pain 2003;7:326-332.
2. Rollman B, Lautenbacher S. Sex differences in musculoskeletal pain. Clin J Pain 2001;17:20-24.
3. Fredriksson L, Alstergren P, Kopp S. Serotonergic mechanisms influence the response to glucocorticoid treatment in TMJ arthritis. Mediators Inflamm 2005;4:194-205.
4. Laursen BS, Bajaj P, Olesen AS, Delmar C, Arendt-Nielsen L. Health related quality of life and quantitative pain measurement in females with chronic non-malignant pain. Eur J Pain 2005;9:267-275.
5. Fredriksson L, Alstergren P, Kopp S. Tumor necrosis factor-alpha in temporomandibular joint synovial fluid predicts treatment effects on pain by intra-articular glucocorticoid treatment. Mediators Inflamm 2006;(6):59425.
6. Syrjanen SM. The temporomandibular joint in rheumatoid arthritis. Acta Radiol Diagn 1985;26:235-243.
7. Tegelberg Å, Kopp S. Subjective symptoms from the stomatognathic system in individuals with rheumatoid arthritis and osteoarthrosis. Swed Dent J 1987;11:11-22.
8. Grassi W, De Angelis R, Lamanna G, Cervini C. The clinical features of rheumatoid arthritis. Eur J Radiol 1998; 27(suppl 1): 18-24.
9. Klimiuk PA, Sierakowski S, Latosiewicz R, Cylwik B, Skowronski J, Chwiecko J. Serum cytokines in different histological variants of rheumatoid arthritis. J Rheumatol 2001;28:1211-1217.
10. Kopp S, Alstergren P. Blood serotonin and joint pain in seropositive versus seronegative rheumatoid arthritis. Mediators Inflamm 2002;11:211-217.
11. Neidel J, Schulze M, Lindschau J. Association between degree of bone-erosion and synovial fluid-levels of tumor necrosis factor alpha in the knee-joints of patients with rheumatoid arthritis. Inflamm Res 1995;44:217-221.
12. Symons JA, Young PR, Duff GW. Soluble type II interleukin 1 (IL-I) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-I receptor antagonist. Proc Natl Acad Sci USA 1995;92:1714-1718.
13. Alstergren P, Benavente C, Kopp S. Interleukin-1beta, interleukin-1 receptor antagonist, and interleukin-1 soluble receptor II in temporomandibular joint synovial fluid from patients with chronic polyarthritides. J Oral Maxillofac Surg 2003;61:1171-1178.
14. Akaogi J, Nozaki T, Satoh M, Yamada H. Role of PGE2 and EP receptors in the pathogenesis of rheumatoid arthritis and as a novel therapeutic strategy. Endocr Metab Immune Disord Drug Targets 2006;6:383-394.
15. McNearney T, Baethge BA, Cao S, Alam R, Lisse JR, Westlund KN. Excitatory amino acids, TNF-alpha, and chemokine levels in synovial fluids of patients with active arthropathies. Clin Exp Immunol 2004;137:621-627.
16. Kopp S, Alstergren P, Ernestam S, Nordahl S, Morin P, Bratt J. Reduction of temporomandibular joint pain after treatment with a combination of methotrexate and infliximab is associated with changes in synovial fluid and plasma cytokines in rheumatoid arthritis. Cells Tissues Organs 2005;180:22-30.
17. Kopp S, Alstergren P, Ernestam S, Nordahl S, Bratt J. Interleukin-1 beta influences the effect of infliximab on temporomandibular joint pain in rheumatoid arthritis. Scand J Rheumatol 2006;35:182-188.
18. Hakala M, Sajanti E, Ikäheimo I, Aho K. High prevalence of rheumatoid factor in community-based series of patients with rheumatoid arthritis meeting the new (1987) ARA criteria: RF-negative non-erosive rheumatoid arthritis is very rare. Scand J Rheumatol 1998;27:368-372.
19. Bukhari M, Lunt M, Harrison BJ, Scott DGI, Symmons DPM, Silman AJ. Rheumatoid factor is the major predictor of increasing severity of radiographic erosions in rheumatoid arthritis: Results from the Norfolk Arthritis Register Study, a large inception cohort. Arthritis Rheum 2002;46:906-912.
20. Scott DL. Prognosis and clinical course. In: Haynes BF, Pisetsky DS, St Clair EW (eds). Rheumatoid Arthritis. Philadelphia: Lippincott Williams & Wilkins, 2004: 26-41.
21. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31:315-324.
22. Isselée H, De Laat A, Bogaerts K, Lysens R. Short-term reproducibility of pressure pain thresholds in masticatory muscles measured with a new algometer. J Orofac Pain 1998;12:203-209.
23. Fredriksson L, Alstergren P, Kopp S. Absolute and relative facial pressure-pain thresholds in healthy individuals. J Orofac Pain 2000;14:98-104.
24. Alstergren, P, Kopp S, Theodorsson E. Synovial fluid sampling from the temporomandibular joint: Sample quality criteria and levels of interleukin-1 beta and serotonin. Acta Odontol Scand 1999;57:6-22.
25. Voog O, Alstergren P, Leibur E, Kallikorm R, Kopp S. Immediate effects of the serotonin antagonist granisetron on temporomandibular joint pain in patients with systemic inflammatory disorders. Life Sci 2000;68: 591-602.
26. Alstergren P, Kopp S. Pain and synovial fluid concentration of serotonin in arthritic temporomandibular joints. Pain 1997;72:137-143.
27. Nordahl S, Alstergren P, Kopp S. Tumor necrosis factor-alpha in synovial fluid and plasma from patients with chronic connective tissue disease and its relation to temporomandibular joint pain. J Oral Maxillofac Surg 2000; 58:525-530.
28. Zeller J, Weissbarth E, Baruth B, Mielke H, Deicher H. Serotonin content of platelets in inflammatory rheumatic diseases. Correlation with clinical activity. Arthritis Rheum 1983;26:532-540.
29. Endresen GK. Evidence for activation of platelets in the synovial fluid from patients with rheumatoid arthritis. Rheumatol Int 1989;9:19-24.
30. Tegelberg A, Kopp S, Huddenius K, Forssman L. Relationship between disorder in the stomatognathic system and general joint involvement in individuals with rheumatoid arthritis. Acta Odontol Scand 1987;45:391-398.